The most important result herein reported is that carbocysteine therapy is capable of significantly reducing circulating miR-21 and IL-8 levels in a specific phenotype of COPD patients characterized by frequent exacerbations and mucus hyperproduction. This evidence concerns the gene CXCL8 and chronic obstructive pulmonary disease.